GSK Gains Vaccine Adjuvant Technology With $300 Mil. Corixa Acquisition
Executive Summary
GlaxoSmithKline will expand Corixa's vaccine adjuvant manufacturing capacity following the $300 mil. acquisition of the biotech company
You may also be interested in...
Fluarix Clears FDA; GSK Buys Vaccine Manufacturing Plant From Wyeth
GlaxoSmithKline is expanding its vaccine manufacturing capability as it prepares for its flu vaccine Fluarix to enter the U.S. market and in anticipation of several vaccine approvals over the next few years
Fluarix Clears FDA; GSK Buys Vaccine Manufacturing Plant From Wyeth
GlaxoSmithKline is expanding its vaccine manufacturing capability as it prepares for its flu vaccine Fluarix to enter the U.S. market and in anticipation of several vaccine approvals over the next few years
Merck Sales Force More Focused, Not Smaller, After Vioxx Withdrawal
Merck sales reps will detail fewer products to fewer doctors under a reorganized structure, the company told analysts during its investor day Dec. 14